Viridian Therapeutics Inc. （VRDN.US）：SC TED Race Heats Up Following SLRN's Prioritization on Lonigutamab

14 August 2024 | 2:40PM EDT Viridian Therapeutics Inc. (VRDN): SC TED Race Heats Up Following SLRN's Prioritization on Lonigutamab On Tuesday 8/13, SLRN (not covered) announced its refocused pipeline strategy prioritizing lonigutamab in thyroid eye disease (TED), discontinuing investments in HS/PsA, and a 33% reduction in force to extend cash runway to mid-2027. Recall that lonigutamab is an SC formulated IGF-1R mAb competing directly with VRDN-003. Early lonigutamab PoC data from 12 patients was disclosed ...